Anogen-Yes Biotech

09/02/2026

A recent review published in Antibodies explores the multiple mechanisms through which anti-TNF-α antibodies may help control inflammation in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.

While anti-TNF-α therapies are well known for neutralizing soluble TNF-α, the review highlights additional actions involving membrane-bound TNF-α, including:

• Complement-dependent cytotoxicity
• Antibody-dependent cellular cytotoxicity
• Apoptosis of membrane TNF-α–expressing cells
• Apoptosis of lamina propria T cells
• Induction of regulatory T cells and macrophages

These multifaceted mechanisms may help explain the effectiveness of anti-TNF-α antibodies such as infliximab, adalimumab, and golimumab in reducing IBD-associated inflammation.

Understanding how therapeutic antibodies act beyond simple cytokine neutralization continues to provide valuable insight into antibody-based therapies and inflammatory disease research.

📖 Read the full review:
https://www.mdpi.com/2073-4468/15/4/71

Inflammatory bowel diseases (IBDs), chronic inflammatory disorders of the gastrointestinal tract, are classified into Crohn’s disease (CD) and ulcerative colitis (UC). Despite differing clinical manifestations, both CD and UC share a common immunopathogenesis, involving excessive production of pro...

08/26/2026

Tiziana Life Sciences has reported PET imaging results from a third MSA patient treated with intranasal foralumab, showing reductions in neuroinflammatory activity in key brain regions affected by the disease.

The patient demonstrated:

• Up to 34% reduction in standardized uptake value (SUV)

• Up to 26% reduction in standardized uptake value ratio (SUVR)

Importantly, these findings were consistent with results previously observed in the first two MSA patients, providing further evidence of the potential biological activity of intranasal foralumab in reducing neuroinflammation.

MSA is a rare and progressive neurodegenerative disease with currently no approved disease-modifying treatments, making continued research in this area especially important.

Tiziana plans to evaluate additional patients to further validate these findings and better understand the potential of intranasal foralumab.

Read the full article: https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-reports-reduction-brain-inflammation-third-multiple

08/19/2026

🍵 Could Three Cups of Green Tea a Day Support Brain Health?

A large study of 8,766 older adults in Japan suggests that regular green tea consumption may be associated with healthier aging of the brain.

Researchers found that participants who drank three cups of green tea per day had about 3% fewer cerebral white matter lesions than those who drank one cup daily. Those consuming 7–8 cups per day had about 6% fewer lesions. White matter lesions are associated with aging and an increased risk of cognitive decline and dementia. 🧠

Green tea is rich in antioxidants, including EGCG and flavonols, compounds being studied for their potential antioxidant and anti-inflammatory effects.

Importantly, the study shows an association—not proof that green tea prevents Alzheimer’s disease. More research is needed to understand whether green tea itself provides a protective effect.

Still, findings like these continue to highlight the fascinating relationship between nutrition, healthy aging, and brain health.

🔗 Read the full article: https://www.alzinfo.org/articles/prevention/three-glasses-of-green-tea-a-day-for-brain-health/

Green tea, a traditional beverage in Asia that has become increasingly popular in the United States in recent years, may be good for the brain, according to a n

08/12/2026

This year marks an incredible milestone for Yes Biotech Laboratories Ltd. — 37 years of commitment to science, quality, and innovation.

Since 1989, we have been proud to support researchers, laboratories, and partners around the world with high-quality antibodies, immunoassays, recombinant proteins, and other life science solutions.

For 37 years, our journey has been built on the trust of our customers, the dedication of our team, and the lasting partnerships we have formed along the way. 💙

As we celebrate this special anniversary, we would like to say a heartfelt thank you to everyone who has been part of our journey.

37 Years of Commitment. Science for a Better Tomorrow. 🧬🔬

Here’s to many more years of discovery, innovation, and partnership!

08/05/2026

Encouraging data presented at AAIC 2026 highlight the growing potential of tau-targeted therapies in the treatment of early Alzheimer's disease.

Biogen's investigational antisense oligonucleotide diranersen (BIIB080) demonstrated:

🔬 50–65% reduction in cerebrospinal fluid (CSF) total tau levels
🧬 Significant reduction in brain tau pathology, measured by tau PET imaging
📉 Slowing of cognitive decline across multiple clinical endpoints, with the 60 mg dose showing the strongest benefit at 18 months
➡️ Advancement into Phase 3 clinical development following positive Phase 2 results

Unlike antibody therapies that target existing tau aggregates, diranersen is designed to reduce the production of all tau isoforms by targeting MAPT mRNA, representing a promising gene-silencing approach to Alzheimer's disease.

As research continues to expand beyond amyloid, advances in tau biology, biomarkers, and novel therapeutic strategies are opening new opportunities for Alzheimer's research and drug development.

At Anogen-Yes Biotech Laboratories, we are committed to supporting neuroscience research with high-quality antibodies, ELISA kits, and research reagents that help accelerate discoveries in neurodegenerative diseases.

Read the full article: https://biogen.gcs-web.com/news-releases/news-release-details/

07/29/2026

As Alzheimer's research continues to evolve, the spotlight at AAIC 2026 is shifting beyond amyloid to tau-targeted therapies, signaling an exciting new chapter in the search for disease-modifying treatments.

While anti-amyloid therapies such as Leqembi® remain the only approved disease-modifying treatments today, growing evidence suggests that tau pathology may play a more direct role in cognitive decline. Researchers are increasingly exploring therapies that target tau, with promising clinical programs from companies including Biogen, Eisai, Lilly, and Voyager Therapeutics.

Key trends emerging from AAIC 2026 include:

🔹 Growing momentum behind tau-targeted therapeutics as the next major treatment strategy.
🔹 Continued importance of amyloid-targeting therapies, particularly when used in the earliest stages of disease.
🔹 Increasing focus on combination approaches that address multiple disease mechanisms rather than relying on a single target.
🔹 Advances in biomarkers and early diagnosis, enabling more personalized treatment strategies.

As the field moves toward precision medicine, high-quality research tools remain essential for biomarker discovery, target validation, and therapeutic development.

At Anogen – Yes Biotech Laboratories, we are proud to support neuroscience research with a broad portfolio of high-quality antibodies, recombinant proteins, ELISA kits, and immunoassay reagents, helping researchers advance the next generation of Alzheimer's diagnostics and therapeutics.

Read the full article here: https://www.biospace.com/drug-development/aaic-2026-tau-targeted-alzheimers-treatments-heat-up-while-amyloid-therapies-persist

The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.

07/15/2026

Alzheimer's research continues to evolve, with advances in diagnosis, treatment, and disease monitoring bringing new hope for patients and families.

Key highlights from the latest updates include:

🔹 Blood-based biomarker tests are playing an increasingly important role in supporting earlier Alzheimer's diagnosis, alongside PET imaging and CSF testing.
🔹 Leqembi® and Kisunla™ remain the only FDA-approved disease-modifying therapies for selected patients with early-stage Alzheimer's disease, with ongoing studies evaluating their long-term effectiveness and safety.
🔹 Research is expanding beyond amyloid, with promising developments in tau-targeted therapies, brain-shuttle antibody technology, combination treatments, and prevention studies.
🔹 Biomarker-guided diagnosis and personalized treatment strategies continue to shape the future of Alzheimer's care.

As our understanding of Alzheimer's disease grows, high-quality research reagents remain essential for biomarker discovery, target validation, and therapeutic development.

At Anogen, we're proud to support neuroscience research with a broad portfolio of monoclonal antibodies, recombinant proteins, and immunoassay solutions.

Read the full article here: https://losaltosneurology.com/2026/07/11/summer-2026-alzheimers-disease-updates/

A neurologist reviews 2026 Alzheimer’s advances, including new blood tests, Leqembi, Kisunla, ARIA safety, prevention trials, and emerging tau therapies.

07/08/2026

The 2026 Alzheimer's disease drug development pipeline highlights encouraging progress in the search for new therapies:

🔹 158 candidate drugs are currently being evaluated across 192 active clinical trials
🔹 73% of therapies are disease-targeting, aiming to slow or prevent disease progression
🔹 35% of pipeline drugs are repurposed therapies, offering new opportunities through existing compounds
🔹 More than 54,000 participants are needed to support ongoing clinical studies
🔹 The biopharmaceutical industry sponsors 59% of all trials and 72% of Phase 3 studies

Beyond anti-amyloid therapies, researchers are increasingly targeting inflammation, immune dysfunction, tau pathology, metabolism, neuroprotection, and other biological pathways, reflecting a more diverse and promising therapeutic landscape.

At Anogen, we are proud to support neuroscience and Alzheimer's research with high-quality monoclonal antibodies, recombinant proteins, and immunoassay reagents for biomarker discovery and translational research.

Read the full article here: https://pubmed.ncbi.nlm.nih.gov/42095064/

The AD drug development pipeline has a growing number of trials and drugs in trials. A diverse array of AD pathophysiological processes is being addressed by drugs in trials.

06/24/2026

📈 The Anti-TNF-α monoclonal antibody market continues to demonstrate strong growth potential, driven by the increasing prevalence of autoimmune and inflammatory diseases worldwide.

Anti-TNF therapies remain a cornerstone in the treatment of conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease. At the same time, several key trends are shaping the future of this market:
🔹 Expansion of biosimilar products, improving accessibility and affordability
🔹 Growing adoption of personalized medicine approaches
🔹 Increased use of digital health tools for patient monitoring and treatment management
🔹 Development of combination therapies to enhance clinical outcomes
🔹 Continued investment in biologics and next-generation antibody technologies

As demand for targeted immunotherapies continues to rise, anti-TNF-α antibodies remain an important focus for innovation, clinical research, and commercial growth.

Read the full article: https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market

At Anogen, we are proud to support immunology and inflammation research with a broad portfolio of monoclonal antibodies, ELISA kits, and research reagents.

Monoclonal antibodies market size was valued at $267.6B in 2025 and is projected to grow from $294.1B in 2026 to $547.3B by 2033, at a CAGR of 9.3%

06/17/2026

The Alzheimer's treatment landscape is evolving rapidly, with researchers expanding beyond traditional symptom management toward therapies that may slow disease progression.

Recent milestones include the FDA approvals of Leqembi® (lecanemab) and Kisunla™ (donanemab), the first disease-modifying treatments designed to target amyloid-beta pathology in Alzheimer's disease.

Looking ahead, scientists are actively exploring:

🔹 Next-generation amyloid-clearing therapies
🔹 Novel therapeutic targets beyond amyloid, including neuroinflammation and neuroprotection
🔹 Oral treatment options to improve accessibility and patient convenience
🔹 Non-invasive approaches such as brain stimulation and focused ultrasound
🔹 Lifestyle interventions that may help reduce Alzheimer's risk

With nearly 200 clinical trials evaluating more than 150 investigational therapies, the future of Alzheimer's research is becoming increasingly diverse and promising. As our understanding of the disease continues to grow, innovative therapeutic strategies may help transform the way Alzheimer's is treated in the years ahead.

Source: BrightFocus Foundation
https://www.brightfocus.org/resource/expanding-the-alzheimers-treatment-landscape-a-2026-forecast/

Learn about the treatments landscape for Alzheimer’s in 2026 and beyond.